Abstract 451P
Background
Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. To reduce the risk of an infusion-related reaction (IRR) with ramucirumab, H1-antihistamines are recommended as premedication. However, IRR is hardly observed in clinical practice in the ramucirumab regimen. The H1-antihistamines have several side effects, such as drowsiness and dizziness, and the use of H1-antihistamines might be restricted for the patients who need to drive a car or for elderly patients. The aim of this study was to investigate the safety of ramucirumab without H1-antihistamines as a premedication in patients with solid cancer.
Methods
We retrospectively reviewed the solid tumour patients who received ramucirumab, including regimen without H1-antihistamines at our institution between 2017 and 2019. The patients who received antiemetic steroid for cytotoxic chemotherapy was also included. The primary endpoint was the incidence of IRR during the infusion in the first cycle. The secondary endpoints were the incidence of IRR at any time and other ramucirumab related adverse events.
Results
Of the 51 patients enrolled (median age, 69.5 years; range 41 - 83), 28 (55%) were male. The origins of cancer were gastric cancer (n = 22), lung cancer (n = 26), and colon cancer (n = 3), respectively. Forty-two patients (82%) received ramucirumab in combination with antiemetic steroid for cytotoxic chemotherapy, and nine patients (18%) received ramucirumab monotherapy without steroid. No IRR was observed in this study (IRR rate, 0%; 95% CI 0 - 0.69). Among the overall 272 infusions, there were no events of IRRs or other ramucirumab related adverse events.
Conclusions
There was no IRRs without H1-antihistamines in our retrospective study. Ramucirumab without H1-antihistamines as premedication would be a favourable option for the patients who had trouble with the side effects of H1 antihistamine.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer
Presenter: Jong Hoon Lee
Session: Poster display session
Resources:
Abstract
98P - Influence of DPYD*9, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients
Presenter: Ashok Varma
Session: Poster display session
Resources:
Abstract
99P - Patient-derived tumour model by new culture method leading to the precision medicine
Presenter: Norikatsu Miyoshi
Session: Poster display session
Resources:
Abstract
100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer
Presenter: Kai-Yuan Lin
Session: Poster display session
Resources:
Abstract
101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
Presenter: Chang Wang
Session: Poster display session
Resources:
Abstract
102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Presenter: Kazuhiro Watanabe
Session: Poster display session
Resources:
Abstract
103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy
Presenter: Yanfei Yang
Session: Poster display session
Resources:
Abstract
104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer
Presenter: Sare Hosseini
Session: Poster display session
Resources:
Abstract
105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer
Presenter: Shuohui Dong
Session: Poster display session
Resources:
Abstract
106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum
Presenter: Yakov Ten
Session: Poster display session
Resources:
Abstract